HCPCS Level II code J3396 denotes the injectable ophthalmic drug verteporfin at a unit of 0.1 mg, used primarily in photodynamic therapy for retinal conditions. Nationally, accurate coding of high-cost specialty injectables like verteporfin affects coverage determination, prior authorization workflows, and outpatient drug reimbursement. Clear identification of the HCPCS code supports consistent billing across ambulatory surgical centers, hospital outpatient departments, and ophthalmology clinics.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how payers typically approach coverage for physician-administered ophthalmic injectables, common billing practices for unit reporting, and coding considerations relevant to facility and professional claims. Readers will find benchmarks on code usage and reimbursement patterns (where available), summaries of relevant payer policy themes such as prior authorization and medical necessity, and clinical context describing the service type and typical sites of service.

This summary presents a national perspective on coding and administrative implications for J3396, supporting revenue cycle, compliance, and clinical staff in applying the correct HCPCS Level II code for verteporfin injections.